Welcome to Medivizor!

You're browsing our sample library. Feel free to continue browsing. You can also sign up for free to receive medical information specific to your situation.

Posted by on Jun 25, 2019 in Prostate cancer | 0 comments

In a nutshell

This study aimed to investigate the outcomes of intermediate risk-risk prostate cancer after different treatments. This study concluded that prostate surgery might have a higher survival than radiotherapy.

Some background

There a several options to treat intermediate-risk prostate cancer (IR-PC). Radical prostatectomy (RP; surgery to remove the prostate) is one option. Radiation therapy can also be used. This can be done as external beam radiation therapy (EBRT; X-ray beams come from outside the body and meet on the tumor), brachytherapy (BT; places a radioactive source into the tumor) or both EBRT and BT (EBRT+BT). Another option is androgen deprivation therapy (ADT). This is an antihormone therapy used to lower the hormones that fuel cancer growth. 

It is unclear which treatment is optimal in terms of survival.

Methods & findings

This study included 10,439 patients with IR-PC. Patients had either RP, EBRT, BT or EBRT+BT. They were followed up for an average of 4.1 years.

There was no significant difference in overall survival between RP and EBRT+BT. However, RP was associated with a 2.37 times higher survival when compared to EBRT alone. It was also associated with a 1.98 times higher survival when compared to BT alone. When ADT was used, there was no significant difference in survival time between groups. 

The bottom line

This study concluded that RP was associated with a higher survival than EBRT or BT alone.

The fine print

This study was based on medical records. Information collected in this way is not always complete. Further direct studies comparing these treatment methods are necessary.

Published By :

Urologic oncology

Date :

May 18, 2019

Original Title :

Survival after radiotherapy vs. radical prostatectomy for unfavorable intermediate-risk prostate cancer.

click here to get personalized updates